• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Progyny Appoints Janet Choi, M.D., as Chief Medical Officer

    4/4/23 9:00:00 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care
    Get the next $PGNY alert in real time by email

    NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY) a leading benefits management company specializing in fertility and family building benefits solutions, today announced the appointment of Janet Choi, M.D., as the company's Chief Medical Officer.

    Dr. Choi brings more than 20 years of experience in the field as a board-certified specialist in Obstetrics and Gynecology and in Reproductive Endocrinology. In her new role, she will lead clinical strategy working closely with the company's executive team and medical advisory board to ensure Progyny offers the highest quality and most effective family building and women's health benefits possible.

    "I am thrilled to officially join the Progyny family after having worked alongside this incredible team for more than three years on the medical advisory board and seeing firsthand how they redefine what a fertility and family building benefit should be," said Dr. Choi. "As a physician in the Progyny network, I have seen how an inclusive and comprehensive employer-sponsored benefit empowers patients and providers to make the best clinical decisions resulting in healthier pregnancies and babies. Growing one's family should not be considered a luxury and I am eager to increase access to high-quality family building care."

    "We are excited to have Dr. Choi join Progyny in her new role as Chief Medical Officer where she will provide her unparalleled knowledge as a distinguished fertility and reproductive health specialist, and further our industry-defining work in the benefits space," said Pete Anevski, CEO of Progyny. "Together with Dr. Choi, we look forward to pioneering new and innovative solutions to some of today's largest hurdles in women's health."

    Prior to Progyny, Dr. Choi was the Medical Director of CCRM New York for the last 7 years. Before CCRM, she was an assistant clinical professor in Obstetrics and Gynecology at Columbia University Medical Center and served as the Director of Onco-fertility and Co-Director of the Fertility Preservation Program. Dr. Choi is board-certified in both Obstetrics and Gynecology and in Reproductive Endocrinology, and has written, published, and lectured extensively on infertility, onco-fertility, and fertility preservation. She is an active member of the American Society for Reproductive Medicine (ASRM), the American College of Obstetricians and Gynecologists (ACOG), as well as the New York Obstetrical Society. She has been selected as one of New York Magazine's Top Doctors as well as a New York Super Doctor annually since 2018; a Castle Connolly Exceptional Woman in Medicine every year since 2019; and has been annually listed with Castle Connolly's "Top Doctors" since 2015.

    Dr. Choi graduated Magna Cum Laude from Harvard University with an A.B. in English literature and earned her medical degree and completed her residency in Obstetrics and Gynecology at Columbia University. She completed her sub-specialty fellowship in Reproductive Endocrinology and Infertility at Weill Cornell Medical College in New York.

    About Progyny

    Progyny (NASDAQ:PGNY) is a leading fertility benefits management company. We are redefining fertility and family building benefits, proving that a comprehensive and inclusive solution can simultaneously benefit employers, patients, and physicians.

    Our benefits solution empowers patients with education and guidance from a dedicated Patient Care Advocate (PCA), provides access to a premier network of fertility specialists using the latest science and technologies, reduces healthcare costs for the nation's leading employers, and drives optimal clinical outcomes. We envision a world where anyone who wants to have a child can do so.

    Headquartered in New York City, Progyny has been recognized for its leadership and growth by CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Financial Times, INC. 5000, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.

    For Further Information, Please Contact:

    Investors:

    James Hart

    [email protected]

    Media:

    Selena Yang

    [email protected]



    Primary Logo

    Get the next $PGNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PGNY

    DatePrice TargetRatingAnalyst
    12/2/2024$17.00Overweight → Neutral
    Analyst
    11/13/2024$26.00 → $19.00Buy → Hold
    Truist
    9/19/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024$37.00 → $24.00Buy → Hold
    Canaccord Genuity
    8/7/2024$31.00 → $25.00Outperform → Market Perform
    Leerink Partners
    8/7/2024Buy → Neutral
    BTIG Research
    7/16/2024$36.00Mkt Outperform
    JMP Securities
    5/10/2024Overweight → Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $PGNY
    SEC Filings

    See more
    • SEC Form 144 filed by Progyny Inc.

      144 - Progyny, Inc. (0001551306) (Subject)

      6/3/25 12:05:25 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Progyny, Inc. (0001551306) (Filer)

      5/28/25 4:37:32 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 10-Q filed by Progyny Inc.

      10-Q - Progyny, Inc. (0001551306) (Filer)

      5/9/25 4:31:42 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Progyny downgraded by Analyst with a new price target

      Analyst downgraded Progyny from Overweight to Neutral and set a new price target of $17.00

      12/2/24 10:07:08 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny downgraded by Truist with a new price target

      Truist downgraded Progyny from Buy to Hold and set a new price target of $19.00 from $26.00 previously

      11/13/24 8:20:07 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny downgraded by JMP Securities

      JMP Securities downgraded Progyny from Mkt Outperform to Mkt Perform

      9/19/24 7:51:03 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chairman Schlanger David J bought $2,202,330 worth of shares (150,000 units at $14.68), increasing direct ownership by 192% to 228,269 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      12/26/24 5:35:03 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • CHIEF EXECUTIVE OFFICER Anevski Peter bought $3,034,084 worth of shares (209,500 units at $14.48), increasing direct ownership by 90% to 441,463 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      12/26/24 5:31:32 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Progyny Joins Amazon's Health Benefits Connector Program as First Women's Health and Family Building Solution

      NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced a new collaboration with Amazon's Health Benefits Connector to expand access to comprehensive women's health services. Through Amazon's Health Benefits Connector, eligible individuals can now seamlessly discover and enroll in Progyny benefits that are available to them through their employer or health plan. Progyny's high-touch, clinically integrated care model is used by over 530 employers and health plans across the U.S., supporting more than 6.7 million lives. The company's benefits span the full reproductive health continuum – includ

      6/10/25 9:02:11 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Adds Distinguished Healthcare Executive Elizabeth Bierbower to Board of Directors

      NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced the addition of healthcare veteran Elizabeth Bierbower to its Board of Directors. "As we continue to round out our board's experience, Elizabeth's extensive leadership with some of the largest health plans and deep financial expertise will be invaluable as we scale and innovate across the women's health and family building spectrum," said Pete Anevski, CEO of Progyny. "Her insights will support our strategy to deliver even more value to our members, clients, and shareholders as we expand our reach and impact." Bierbower brings more than

      5/29/25 9:03:40 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • Progyny Appoints Two Renowned Women's Health Experts to Medical Advisory Board

      NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (NASDAQ:PGNY), a global leader in women's health and family building solutions, today announced the appointment of Morehouse School of Medicine's Regional Dean for Seattle and Puget Sound's Dr. Gloria Richard-Davis – a double-board certified physician in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, a fellow of the American College of Obstetricians & Gynecologists (FACOG), and a Menopause Society Certified Practitioner (MSCP) – and Columbia University's Dr. Whitney Booker – a double-board certified physician in Obstetrics and Gynecology and Maternal-Fetal Medicine – to its Medical Advisory Board. "As Pr

      5/14/25 9:05:48 AM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care

    $PGNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Scott Cheryl sold $59,037 worth of shares (2,675 units at $22.07), decreasing direct ownership by 16% to 14,112 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      6/12/25 5:07:13 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • EVP, GC Swartz Allison covered exercise/tax liability with 339 shares, decreasing direct ownership by 0.41% to 82,095 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      6/5/25 5:23:09 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care
    • CHIEF FINANCIAL OFFICER Livingston Mark S. covered exercise/tax liability with 339 shares, decreasing direct ownership by 0.47% to 72,172 units (SEC Form 4)

      4 - Progyny, Inc. (0001551306) (Issuer)

      6/5/25 5:18:40 PM ET
      $PGNY
      Misc Health and Biotechnology Services
      Health Care